Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Fineline Cube Mar 10, 2026
Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Fineline Cube Mar 10, 2026
Company Drug

Bristol-Myers Squibb Releases Five-Year Data on Sotyktu’s Long-Term Efficacy and Safety

Fineline Cube Feb 18, 2025

In a recent announcement, US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) unveiled the latest...

Company Drug

Wanbangde New Building Materials’ Mecobalamin Earns FDA Orphan Drug Designation for ALS

Fineline Cube Feb 18, 2025

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) announced that its mecobalamin product has...

Company Drug

Biokin Pharmaceutical Registers Phase III Study for BL-B01D1 in EGFR Mutant NSCLC

Fineline Cube Feb 18, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has registered a Phase III study on chinadrugtrials.org.cn...

Company Drug

AccurEdit’s ART002 Becomes First In Vivo Gene Editing Product to Reduce LDL-C in Humans

Fineline Cube Feb 18, 2025

Suzhou-based gene editing specialist AccurEdit Therapeutics announced that its in vivo gene editing product, ART002,...

Company Deals

Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market

Fineline Cube Feb 18, 2025

China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the...

Company Drug

Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study

Fineline Cube Feb 18, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...

Company Deals

PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development

Fineline Cube Feb 18, 2025

PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...

Company Drug

Samsung Bioepis’ Ospomyv and Xbryk Gain FDA Approval for RANKL Inhibitor Biosimilars

Fineline Cube Feb 17, 2025

South Korea-based Samsung Bioepis Co., Ltd. announced that it has received marketing approval from the...

Company Drug

Kexing Biopharm’s GB05 Receives FDA Approval for Pediatric RSV Infections

Fineline Cube Feb 17, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...

Company Drug

Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment

Fineline Cube Feb 17, 2025

The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar...

Company Deals

Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study

Fineline Cube Feb 17, 2025

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675)’s controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd.,...

Company Drug

GSK’s Penmenvy Meningococcal Vaccine Approved by FDA for Ages 10-25

Fineline Cube Feb 17, 2025

UK-based multinational GSK plc (LON: GSK) announced that it has received marketing approval from the...

Company Deals

3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China

Fineline Cube Feb 17, 2025

China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...

Company Drug

LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites

Fineline Cube Feb 17, 2025

Germany-based LINDIS Biotech GmbH announced that it has received market approval from the European Commission...

Company Drug

IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma

Fineline Cube Feb 17, 2025

China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...

Company Drug

Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC

Fineline Cube Feb 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...

Company Deals

Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m

Fineline Cube Feb 17, 2025

Tianyi Medical (SHE: 301097), a Ningbo-based developer of Class III medical consumables, has announced plans...

Company Drug

Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents

Fineline Cube Feb 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...

Company Drug

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval

Fineline Cube Feb 17, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...

Company

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology

Fineline Cube Feb 16, 2025

In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...

Posts pagination

1 … 178 179 180 … 632

Recent updates

  • SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure
  • Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential
  • Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors
  • Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market
  • GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.